Cadila Pharma Looks for Acquisitions in Europe, US (India)
This article was originally published in PharmAsia News
Cadila Pharmaceuticals Ltd. is one of India's leading drug manufacturers. The company has also already put down roots in America, Africa, Central and South-East Asia, Japan, Middle East and Europe. Cadila is now looking for acquisitions within regulated international markets that will help it better cultivate its brand across the globe. It is specifically targeting companies with established pharmaceutical or biotechnology products. Cadila's hope is to close a deal that will allow it the same penetration of regulated markets as it already enjoys in its production of generic drugs within unregulated markets in India and several parts of Africa. (Click here for more
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.